DOJ watchdog reviews DEA fentanyl walk tactic
Analysis based on 11 articles · First reported Aug 17, 2026 · Last updated Aug 17, 2026
The review could lead to stricter enforcement policies and potential legal liabilities for the DEA, affecting government contractors and pharmaceutical supply chains. Public scrutiny may increase pressure on federal agencies, but direct market impact is limited as the entities involved are government bodies.
The U.S. Justice Department's Inspector General, Don Berthiaume, announced a review of a controversial United States — Drug Enforcement Administration tactic in which agents allowed fentanyl shipments to reach the streets to build larger cases against traffickers. The review follows an Associated Press investigation revealing that DEA agents in Mexico repeatedly monitored but did not seize major fentanyl shipments between 2023 and 2025, including a delivery of 74,000 pills in United States — Albuquerque, New Mexico. DEA Administrator Terence Cole requested a narrower inquiry, and whistleblower Agent David Howell, represented by Empower Oversight, alleges federal authorities 'poisoned our community to make cases.' Mexico Attorney General Raúl Torrez has threatened to sue the Justice Department over its refusal to provide records. The review will examine policies over the past two years and could determine whether similar shipments were allowed in other cities.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard